Date: 2016-06-29
Type of information: Development agreement
Compound: high-throughput sequencing platform
Company: Integragen (France) AP-HP The Greater Paris University Hospitals (France)
Therapeutic area: Technology - Services
Type agreement: collaboration development
Action mechanism:
Disease:
Details: * On June 29, 2016, The Greater Paris University Hospitals, AP-HP and the molecular genomics company IntegraGen announced today the signature of an agreement to develop a high-throughput sequencing platform (exome and whole genome) to be utilized for research projects and clinical research initiatives. This three-year research partnership aligns with a major objective of the AP-HP’s 2015-2019 Strategic Plan related to providing clinicians and patients access to newer health innovations and technological advancements. The agreement was approved by the Executive Board of the AP-HP on June 28, 2016. Through the framework of this agreement, researchers, clinicians, and biologists of the AP-HP will benefit from IntegraGen’s experience and expertise in large scale, industrial high throughput sequencing projects and its ability to deliver high quality data. This represents a major breakthrough for researchers at AP-HP since some were obliged to send DNA abroad to be sequenced prior to this agreement. This agreement represents an essential first step in the development of a formalized national personalized medicine initiative as a part of the French Plan for Genomic Medicine 2025. The current initiative will enable sequencing data collected from biological samples to be transformed into genomic information and molecular diagnostic tools. The common high-throughput sequencing platform developed as a result of this agreement will be utilized for research projects in the fields of cancer, rare diseases, microbiology, and potentially psychiatry. Researchers utilizing this platform will have access to an integrated solution encompassing all stages of genomic analysis, from the collection of the biological sample to the delivery of sequencing results. The framework of the current agreement will also allow for the development of additional ambitious research projects and cooperative initiatives with outside research partners such as academic universities and INSERM.
Financial terms:
Latest news:
